Pfizer breast cancer drug gets breakthrough label

April 10, 2013 by The Associated Press

Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.

Pfizer shares jumped nearly 3 percent following the news.

The breakthrough designation is meant to speed up development and review of experimental treatments seen as big advances.

The drug, palbociclib (pal-boh-SEYE'-clib), is being evaluated as an initial treatment for a subgroup that includes about 60 percent of postmenopausal women whose breast cancer is locally advanced or has spread elsewhere in the body. Their tumors are fueled by the .

Pfizer is currently running a late-stage study of palbociclib, comparing its effects in combination with letrozole with the effects of letrozole alone. Letrozole, sold under the brand Femara, blocks production of estrogen.

Explore further: Late treatment with letrozole can reduce breast cancer recurrence risk

shares

Related Stories

Afinitor approved for advanced breast cancer

July 23, 2012

(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...

SABCS: PD 0332991 + letrozole studied in ER+ breast cancer

December 5, 2012

(HealthDay)—For women with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the investigational agent PD 0332991 plus letrozole improves progression-free survival versus ...

New drug regimens may slow advanced breast cancer

December 5, 2012

(HealthDay)—An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies reported Wednesday.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.